Indications & Dose: ACID-RELATED DYSPEPSIA PO Adult 15 or 30mg OD for 2-4 wk | EROSIVE ESOPHAGITIS PO Adult 30mg OD up to 8 wk Child 1-11 yr: <30 kg: 15mg OD 12 wk, >30 kg: 30mg OD 12 wk, 12-17 yr: 30mg OD 8 wk | GASTRIC ULCER PO Adult 30mg/day 8 wk | GASTROESOPHAGEAL REFLUX DISEASE PO Adult 15mg/day 8 wk Child 1-11 yr: <30 kg: 15mg OD 12 wk, >30 kg: 30mg OD 12 wk, 12-17 yr: 30mg OD 8 wk | H.PYLORI ERADICATION Combination therapy PO Adult 30mg TID with amoxicillin 1g TID 14 days or 30mg BID with amoxicillin 1g & clarithromycin 500mg BID 10-14 days | H.PYLORI INFECT Short-term therapy PO Adult 15mg OD 4 wk, MD 15mg OD | HYPERSECRETORY CONDITIONS PO Adult Initially 60mg OD, adjust dose based on patient response, doses >120mg/day given in divided doses | NON-EROSIVE ESOPHAGITIS PO Child 12-17 yr: 15mg OD 8 wk | NSAID-INDUCED GASTRIC ULCERS PO Adult 30mg OD 8 wk | Prophylactic therapy PO Adult 15mg OD 12 wk

Precautions: Hepatic impairment, malignancy

ADR: Serious: Hypersensitivity reactions, angioedema, raised liver enzymes, Others: fever, insomnia, somnolence, agitation, depression, hallucinations, headache, confusion, anxiety, malaise, nausea, vomiting, constipation, diarrhea, abdominal pain

DDI: Serious Dipyridamole bioavailability reduces, Vecuronium duration of neuromuscular blockade increases, Methotrexate excretion reduces, Fluvoxamine inhibits drug metabolism, Levothyroxine leads to increase TSH levels by drug, Mycophenolate levels reduces, Carbamazepine levels reduces by drug, Clarithromycin/Anti-neoplastics/Digoxin/Tacrolimus levels rises, Antacids reduces drug bioavailability

Diet: Before food(breakfast)

Monitor: CBC, liver function, renal function & serum gastrin levels